On decision rules, cost-effectiveness, and budget impact

被引：0

作者：

Luis Pinto, Jose ^{[2
]}

Antonio Sacristan, Jose ^{[3
]}

Antonanzas, Fernando ^{[1
]}

机构：

[1] Univ La Rioja, Dept Econ & Empresa, Fac Ciencias Empresariales, Logrono 26004, Spain

[2] Univ Pablo de Olavide, Seville, Spain

[3] Labs Lilly, Madrid, Spain

来源：

GACETA SANITARIA | 2008年 / 22卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

页码：585 / 589

页数：5

共 12 条

[1]

ALVAREZDARDET C, 2007, RAZONES DECIDIR CON

[2] Rationing - How much will Herceptin really cost? [J].

Barrett, Ann ;

Roques, Tom ;

Small, Matthew ;

Smith, Richard D. .

BRITISH MEDICAL JOURNAL, 2006, 333 (7578) :1118-1120A

[3] Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses - Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial [J].

Cohen, DJ ;

Bakhai, A ;

Shi, CX ;

Githiora, L ;

Lavelle, T ;

Berezin, RH ;

Leon, MB ;

Moses, JW ;

Carrozza, JP ;

Zidar, JP ;

Kuntz, RE .

CIRCULATION, 2004, 110 (05) :508-514

[4]

*DEP HLTH, 2002, PROGR BUDG

[5] Cost-effectiveness of a 'score and scope' strategy for the management of dyspepsia [J].

García-Altés, A ;

Rota, R ;

Barenys, M ;

Abad, A ;

Moreno, V ;

Pons, JMV ;

Piqué, JM .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (07) :709-719

[6] Congestive heart failure in Spain:: cost-effectiveness and cost-benefit analyses of treatment with β-blockers [J].

Manglano, JD .

REVISTA CLINICA ESPANOLA, 2005, 205 (04) :149-156

[7]

Muñoz-Carlin MD, 2007, REV INVEST CLIN, V59, P197

[8]

PINTO JL, 2006, EKONOMIAZ, V60, P192

[9] Cost-effectiveness analysis in the economic assessment of health interventions [J].

Prieto, L ;

Sacristán, JA ;

Antoñanzas, F ;

Rubio-Terrès, C ;

Pinto, JL ;

Rovira, J ;

Grupo, ECOMED .

MEDICINA CLINICA, 2004, 122 (13) :505-510

[10]

REJAS J, 2003, REV ESP EC SALUD, V2, P366

← 1 2 →